BARASCH JONATHAN has a total of 12 patent applications. Its first patent ever was published in 2006. It filed its patents most often in United States and WIPO (World Intellectual Property Organization). Its main competitors in its focus markets measurement, pharmaceuticals and biotechnology are OPEXA THERAPEUTICS INC, GURBEL PAUL A and COUNTERPOINT HEALTH SOLUTIONS INC.
# | Country | Total Patents | |
---|---|---|---|
#1 | United States | 8 | |
#2 | WIPO (World Intellectual Property Organization) | 4 |
# | Industry | |
---|---|---|
#1 | Measurement | |
#2 | Pharmaceuticals | |
#3 | Biotechnology | |
#4 | Environmental technology |
# | Name | Total Patents |
---|---|---|
#1 | Barasch Jonathan | 12 |
#2 | Paragas Neal | 4 |
#3 | Nickolas Thomas L | 4 |
#4 | Barasch Nicholas | 2 |
#5 | Deng Shixian | 1 |
#6 | Seth Pankaj | 1 |
#7 | Landry Donald W | 1 |
#8 | Forster Catherine | 1 |
#9 | Sukhatme Vikas P | 1 |
#10 | Parravicini Elvira | 1 |
Publication | Filing date | Title |
---|---|---|
WO2012068545A1 | Ngal in acute kidney injury | |
US2012083421A1 | Use of urinary ngal to diagnose and monitor hiv-associated nephropathy (hivan) | |
US2010233740A1 | Use of urinary ngal to distinguish kidney disease and predict mortality in subjects with cirrhosis | |
US2010233739A1 | Use of urinary ngal to diagnose unilateral and bilateral urinary obstruction | |
WO2010045585A2 | Use of urinary ngal to diagnose and monitor hiv-associated nephropathy (hivan) | |
WO2006078717A2 | Lipocalin 2 for the treatment, prevention, and management of cancer metastasis, angiogenesis, and fibrosis |